Patent ID: 8672857
Filing Date: 2014-03-18
Classification: G01N

Abstract:
1. A method of predicting responsiveness to cardiac resynchronization therapy of a human who is a candidate for or has been treated with cardiac resynchronization therapy, the method comprising measuring a galectin-3 blood concentration in a sample from the human, thereby to determine presence or absence of a galectin-3 blood concentration in the human predictive of responsiveness to cardiac resynchronization therapy, wherein the galectin-3 blood concentration in the human is determined to be above a minimum threshold of between 25 and 30 ng/ml, and wherein the measuring is performed using an immunoassay comprising the steps: contacting the sample with a first antibody immobilized on a solid surface and capable of binding to galectin-3, wherein the first antibody captures the galectin-3 in the sample to form a first complex; contacting the first complex with a second antibody comprising a detectable label and capable of binding to galectin-3, wherein the second antibody binds to the first complex to form a second complex comprising the detectable label; and detecting the detectable label of the second complex, thereby detecting the galectin-3 blood concentration in the sample.